Sarepta Therapeutics Inc
SRPT21.610USD
+0.670+3.20%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.12BMarktkapitalisierung
9.03KGV TTM
mehr Informationen über Sarepta Therapeutics Inc Unternehmen
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Unternehmensinformationen
BörsenkürzelSRPT
Name des UnternehmensSarepta Therapeutics Inc
IPO-datumJun 04, 1997
Gegründet am2013
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Anzahl der mitarbeiter1372
WertpapierartOrdinary Share
GeschäftsjahresendeJun 04
Addresse215 1st St Ste 415
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142-1213
Telefon16172744000
Websitehttps://www.sarepta.com/
BörsenkürzelSRPT
IPO-datumJun 04, 1997
Gegründet am2013
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Apr 6
Währung: USDAktualisiert: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.64B
86.11%
Rest of World
150.25M
7.90%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Aktionärsstatistik
Aktualisiert: Mon, May 19
Aktualisiert: Mon, May 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Aktionäre
Aktionäre
Anteil
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.91%
Investment Advisor/Hedge Fund
37.22%
Hedge Fund
9.45%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.10%
Pension Fund
1.10%
Sovereign Wealth Fund
1.09%
Venture Capital
0.33%
Institutionelle Beteiligung
Aktualisiert: Mon, Jan 20
Aktualisiert: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1045
100.62M
102.55%
-5.73M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
2022Q4
996
84.01M
95.72%
-10.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital International Investors
8.70M
8.96%
+2.44M
+38.95%
Dec 31, 2024
The Vanguard Group, Inc.
9.07M
9.34%
+117.52K
+1.31%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.94M
9.21%
+162.26K
+1.85%
Dec 31, 2024
Capital Research Global Investors
5.93M
6.11%
+49.00
+0.00%
Feb 28, 2025
State Street Global Advisors (US)
4.07M
4.19%
-200.90K
-4.70%
Dec 31, 2024
Janus Henderson Investors
4.33M
4.46%
-30.19K
-0.69%
Dec 31, 2024
Barry (Richard J)
3.18M
3.28%
+2.38K
+0.07%
Mar 10, 2025
Avoro Capital Advisors LLC
2.56M
2.63%
--
--
Dec 31, 2024
Wellington Management Company, LLP
2.07M
2.13%
-657.84K
-24.13%
Dec 31, 2024
Farallon Capital Management, L.L.C.
2.87M
2.95%
+285.10K
+11.05%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
Global X Genomics & Biotechnology ETF
2.35%
First Trust NYSE Arca Biotechnology Index Fund
2.26%
iShares Neuroscience and Healthcare ETF
1.65%
Tema Neuroscience and Mental Health ETF
1.2%
WisdomTree BioRevolution Fund
0.92%
Harbor Human Capital Factor Unconstrained ETF
0.87%
SPDR S&P Biotech ETF
0.82%
VanEck Biotech ETF
0.74%
Invesco S&P MidCap 400 Pure Growth ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil2.35%
First Trust NYSE Arca Biotechnology Index Fund
Anteil2.26%
iShares Neuroscience and Healthcare ETF
Anteil1.65%
Tema Neuroscience and Mental Health ETF
Anteil1.2%
WisdomTree BioRevolution Fund
Anteil0.92%
Harbor Human Capital Factor Unconstrained ETF
Anteil0.87%
SPDR S&P Biotech ETF
Anteil0.82%
VanEck Biotech ETF
Anteil0.74%
Invesco S&P MidCap 400 Pure Growth ETF
Anteil0.57%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.54%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
